KEYMED BIOSCIENCES -0001 (64Z) — Financial Flexibility Index
KEYMED BIOSCIENCES -0001 (64Z) has a Financial Flexibility Index of -0.26x as of December 2025. Free cash flow of €-375.93 Million (operating CF €-712.41 Million minus capex €336.48 Million) represents 0% of total liabilities (€1.44 Billion). Also explore 64Z shareholders equity momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
KEYMED BIOSCIENCES -0001 Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for KEYMED BIOSCIENCES -0001 across 5 annual periods. Check KEYMED BIOSCIENCES -0001 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Annual Financial Flexibility Index for KEYMED BIOSCIENCES -0001 (2021–2025)
Year-by-year free cash flow to debt coverage for KEYMED BIOSCIENCES -0001. For the full company profile including market capitalisation, see market cap of KEYMED BIOSCIENCES -0001.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.26x | €-375.93 Million | €-712.41 Million | €1.44 Billion | ▲ +41.5% |
| 2024 | -0.45x | €-575.14 Million | €-789.63 Million | €1.29 Billion | ▼ -605.3% |
| 2023 | 0.09x | €78.99 Million | €-303.62 Million | €896.11 Million | ▲ +142.7% |
| 2022 | -0.21x | €-122.39 Million | €-401.93 Million | €593.10 Million | ▼ -42.8% |
| 2021 | -0.14x | €-41.78 Million | €-214.64 Million | €289.07 Million | — |